Full-Time

Clinical Imaging Director

Confirmed live in the last 24 hours

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

Compensation Overview

$181.8k - $232.6k/yr

+ Bonus + Stock-based long-term incentives

Senior, Expert

Remote in USA

Category
Diagnostics & Laboratory Professionals
Medical, Clinical & Veterinary
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Amgen referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Doctorate degree PhD OR PharmD OR MD [and relevant post-doc where applicable] and 5 years of biomedical or imaging-related field experience
  • Master’s degree and 8 years of biomedical or imaging-related field experience
  • Bachelor’s degree and 10 years of biomedical or imaging-related field experience
Responsibilities
  • Expand Amgen’s end to end imaging process to all non-oncology TAs and integrate into wider clinical development procedures. Initial focus would be on obesity, inflammation and rare diseases.
  • Representing clinical imaging on process improvement initiatives
  • Standardize internal document templates and imaging vendor documentation (Charter, site manuals etc.) for common imaging readouts. Establish new procedures and documentations for novel or updated imaging procedures/criteria.
  • Serve as a SME while supporting strategic sourcing and vendor management teams in vendor capability/quality evaluations.
  • Develop training materials for imaging methods and endpoints to educate team members on expected/appropriate imaging strategies in clinical trials.
  • Work closely with precision medicine, statistics, clinical development, regulatory and clinical operation leads to formulate appropriate imaging biomarker strategies
  • Lead, design and implement multi-modality imaging measures as endpoints for clinical studies in a variety of TAs.
  • Contribute to clinical biomarkers and diagnostics strategy by evaluating novel imaging modalities, novel image analysis tools and artificial intelligence tools.
Desired Qualifications
  • An advanced degree (i.e., MSc or Ph.D.) with 7+ years of experience in clinical imaging research working within a pharmaceutical company.
  • Proven track record of successfully leading and managing clinical trials with a deep understanding the workflows which allow different teams (regulatory, operations, statistics etc.) to successfully collect and analyze imaging data.
  • Proven leadership experience in the utilization of molecular imaging as a quantitative biomarker in clinical trials.
  • Experience with the utilization of clinical MR imaging in evaluation of clinical endpoints and investigation of suspected adverse events is preferred.
  • Experience is utilization of imaging in obesity and rare diseases is preferred.

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are derived from living organisms, to address conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a large portion of its earnings to discover new therapies. The goal of Amgen is to improve patient care by providing effective therapeutic solutions and expanding its pipeline of potential new treatments.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen's investment in AI aligns with trends in biotechnology innovation.
  • Institutional investments indicate strong market confidence in Amgen's growth.
  • FTC clearance of the Horizon merger may ease future regulatory hurdles.

What critics are saying

  • Competitors' AI-driven drug discovery could outpace Amgen's traditional R&D methods.
  • FTC scrutiny of mergers may complicate Amgen's future growth strategy.
  • Advancements in quantum technologies could pose a competitive threat to Amgen.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline of potential new therapies in development.
  • Amgen's acquisition of Horizon Therapeutics enhances its rare disease portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.

BioSpace
Sep 19th, 2023
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans

The consent agreement struck between the FTC and Amgen and Horizon Therapeutics could have significant implications for ongoing and future M&A challenges, experts told BioSpace.